| Document Date: 2014-08-12 13:02:41
Open Document File Size: 111,63 KBShare Result on Facebook
City Princeton / New York / / Company Pfizer Inc / Bristol-Myers Squibb Company / Saag KG / CCP / / Country United States / / Event Person Communication and Meetings / FDA Phase / / Facility American College / National Library of Medicine / / IndustryTerm clinical and imaging study / treatment of rheumatic diseases / / MedicalCondition systemic lupus erythematosus / rheumatoid nodules / severe anti-TNFalpha refractory juvenile idiopathic arthritis-related uveitis / active ankylosing spondylitis / arthritis / high disease / psoriasis vulgaris / rheumatic diseases / rheumatoid arthritis / Crohn's disease / early rheumatoid arthritis / methotrexate-resistant active rheumatoid arthritis / diabetes / extraarticular disease / Felty’s syndrome / ulcerative colitis / tumor necrosis / very early rheumatoid arthritis / RA vasculitis / juvenile idiopathic arthritis / undifferentiated inflammatory arthritis / lupus nephritis / inflammatory condition / Psoriatic arthritis / uveitis / / Organization Paediatric Rheumatology INternational Trials Organization / FDA / American College of Rheumatology / / Person Care Res (Hoboken) / Arch Clin / Ann Rheum / Ann Intern / / / Position physician / / Product Humira / Orencia / Kineret / SC / Rituxan / Enbrel / SC injection / Remicade / Authorization Criteria / / ProvinceOrState South Carolina / / Technology alpha / antibodies / / URL http /
SocialTag |
PRIOR AUTHORIZATION POLICY Orencia® (abatacept) Subcutaneous [SC] injection: To Initiate a Coverage Review, Call[removed]Intravenous [IV] infusion: To initiate a Coverage Review, Call[removed]OVERVIEW